Skip to main content
. Author manuscript; available in PMC: 2014 Jul 1.
Published in final edited form as: J Hepatol. 2013 Feb 21;59(1):131–137. doi: 10.1016/j.jhep.2013.02.007

Table 3.

Baseline fibrosis score in patients with different types of lipodystrophy

Fibrosis Score AGL
(N=13)
(Age 9–68
years)
APL
(N=5)
(Age 10–
30 years)
CGL;
AGPAT2
(N=8)
(Age 14
47 years)
CGL;
BSCL2
(N=10)
(Age 8–18
years)
FPL;
LMNA
(N=12)
(Age 18–64
years)
FPL;
PPARY
(N=2)
(Age 32
and 35
years)
0 (None) 2 0 0 0 4 1
1A (Mild
perisinusoidal only)
0 0 3 0 3 0
1B (Moderate
perisinuosoidal)
1 1 1 0 0 0
1C (Periportal only) 1 0 1 0 1 0
2 (Periportal and
perisinusoidal)
2 2 2 1 2 1
3 (Bridging fibrosis) 41 2 12 4 2 0
4 (Cirrhosis) 3 0 0 5 0 0

AGL, Acquired Generalized Lipodystrophy; CGL, Congenital Generalized Lipodystrophy; FPL, Familial Partial Lipodystrophy; APL, Acquired Partial Lipodystrophy.

1

Three out 4 patients in the AGL group with bridging fibrosis also had autoimmune hepatitis

2

The patient with AGPAT2 mutation in the CGL group who had bridging fibrosis also had concomitant hepatitis B.

HHS Vulnerability Disclosure